Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Docetaxel and Bevacizumab in SCLC
NCT00755157Phase 2Withdrawn
- Sponsor
- University Hospital of Crete
- Start
- Apr 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, bevacizumab in small cell lung cancer (SCLC), sponsored by University Hospital of Crete. Planned start Apr 2008; status: withdrawn.
02
Drugs
docetaxelbevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00755157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755157.